Logo

First-ever Immune Cell Delivery Technology

Immune cells as natural couriers for precision therapeutics

First-ever Immune Cell Delivery Technology

Immune cells as natural couriers for precision therapeutics.

It all starts inside the cell

1

The human immune cells have been shaped over millions of years of evolution to reach, penetrate, and migrate through all body tissues – identifying and targeting specific threats with remarkable precision.

2

Edity has developed an advanced AI-powered platform to engineer therapeutic proteins and optimize them for targeted delivery through the immune system.

3

These immune cells serve as intelligent carriers, transporting the AI-engineered therapeutic proteins directly to diseased tissues, where they are specifically activated to induce precise pathophysiological changes that treat the underlying condition.

In nature, immune cells deliver a toxic payload to eliminate diseased cells

Immune cells are capable of active deep tissue penetration and intracellular protein delivery.

WE LEVERAGE ADVANCED AI ALGORITHMS TO ENGINEER PROTEINS AND THEN USE IMMUNE CELLS TO ENABLE THEIR TARGETED DELIVERY

This opens up a new universe of targets for treatment that have not previously been translated to the clinic.

Edity Tech integrates therapeutic proteins into the secretory vesicles of lymphocytes for precise delivery to target tissues

Sophisticated protein design and highly efficient transformation protocols ensure superior protein expression and transferability

Plug And Play Technology

Builds on clinical grade technologies

  • Compatible with allogeneic approaches.

  • Shown to work with T-cells, NK cells.

  • Edity’s technology can use CAR, TCR or similar modalities for homing and activation.

Plug And Play Technology

Builds on clinical grade technologies

Compatible with allogeneic approaches.

Shown to work with T-cells, NK cells.

Edity’s Technology can use CAR, TCR
or similar modalities for homing
and activation.

Creating new modalities
for intracellular therapy

We deliver proteins to cells anywhere in the body

Creating new modalities
for intracellular therapy

We deliver proteins to cells anywhere in the body

ABOUT US

Edity Therapeutics has developed a groundbreaking platform technology that delivers therapeutic proteins with exceptional precision and efficiency. This technology unlocks the potential to modulate previously inaccessible intracellular targets, offering new hope for treating a wide range of diseases.

The company has initiated an investigational clinical program, to increase the efficacy of CAR T therapy in solid tumors. We simultaneously target tumor cells and use these cells to deliver AI-designed pro-inflammatory proteins to reprogram the tumor microenvironment.

VISION

To transform the future of medicine with the first-ever immune cell delivery technology

MISSION​

At Edity Therapeutics we are creating a new category of immune-cell based therapies to improve the lives of patients with severe disease

VALUES

EMPOWERING

We empower each other to solve problems boldly, embracing and respecting diverse perspectives.

INNOVATION

is at our core; we have courage to explore new ideas

IMPACTFUL

We inspire each other to deliver results

RESILIENCE

Despite setbacks, we are resilient

COLLABORATIVE

We are highly collaborative we support each other to make the best possible teams

Our People

Eyal is a serial entrepreneur and has devoted the majority of his career to building medical device companies. He founded TopSpin medical, Pi-Cardia and Clear-Cut.

Eyal Kolka​

CO-FOUNDER, CHAIRMAN OF THE BOARD​

Michal is graduate of the Weizmann Institute of Science and a seasoned expert in gene editing and genetic screening, having spent four years at Emendo before going onto found her own company, Applied Genetics. Michal founded Edity in 2020.

Michal Golan-Mashiach
PhD, MBA

CO-FOUNDER AND CEO

Abigail is a veteran biotech executive. She has global experience leading corporate strategy, business development and operations across several early-stage companies, with expertise in cell therapies.

Abigail Bracha

BUSINESS DEVELOPMENT

Ofer is an expert in tumor immunology and has gained a strong industrial experience in Compugen focusing on target validation of immuno-oncology programmes.

Ofer Levy, PhD

VP R&D

Sharon is an experienced biochemist and renowned oligo nucleotides expert. At QBI, she headed the entire planning of pre-clinical studies the pre-clinical siRNA pipeline, including in vitro and in vivo trials.

Sharon Avkin Nachum, PhD​

VP TECHNOLOGY 

Zoya brings expertise in cancer immunology and translational research, with strong leadership in advancing immuno-oncology programs. Previously, she held senior roles at Compugen, leading research from discovery to early clinical development.

Zoya Alteber, PhD

VP PRECLINICAL DEVELOPMENT

Advisors

Sandra is a seasoned biotech executive and serial entrepreneur with 30 years of company building across multiple therapeutics modalities. Formerly served as founder and COO at Editas Medicine, Inc

Sandra Glucksmann

Board Member

Hy Levitsky, MD, was President of R&D at Century Therapeutics, EVP and CSO at Juno Therapeutics, and led cancer immunotherapy at Roche. He trained in oncology after earning his MD from Johns Hopkins in 1984.

Hy Levitsky

Drew M. Pardoll, MD, PhD, is Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins. A globally recognized pioneer in tumor immunology, his foundational research laid the groundwork for modern immune checkpoint blockade, therapeutic cancer vaccines, and T-cell therapies that transform how we treat cancer.

Drew M. Pardoll, MD, PhD

is an internationally recognized expert in T-cell therapy and immunotherapy. He brings over 25 years of experience and expertise in cell therapy, including C-level and executive roles at Janssen, Eli Lilly and ArsenalBio,and is a co-inventor of the CART-19 technology from the University of Pennsylvania.

Michael Kalos, PhD

Advisor for oncology and translational medicine. Medical expert in all stages of drug development in oncology with 30+ years of experience in academia (Karolinska) and big pharma (Roche). Current position: Founder and CEO of piMed Consulting.

Pavel Pisa, M.D. Ph.D.

Professor Yoram Reiter from the Technion institute of technology is a world leader in immunotherapy. His research is focused on targeting the intracellular proteome, T cell biology and CAR-T cell engineering

Yoram Reiter, PhD

Investors

Publications

Publications

Contact us

+972-54-7414417
info@edity-tx.com
10 Menachem Plaut St.
7670609, Rehovot, IL
Linkedin